Dare Bioscience, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1.0M | $9.8K | $2.8M | $10.0M | $0 | — | — |
| Cost of Revenue | — | $295.8K | $0 | — | — | — | — | — |
| Gross Profit | — | $734.4K | $9.8K | — | — | — | — | — |
| Gross Margin | — | 71.3% | 100.0% | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $5.5M | $14.3M | $21.5M | $30.0M | $30.6M | $20.8M | $8.5M |
| SG&A Expense | — | $8.8M | $9.2M | $12.1M | $11.2M | $8.4M | $6.5M | $5.3M |
| Operating Income | — | $-13.6M | $-23.5M | $-30.9M | $-31.4M | $-39.1M | $-27.4M | $-14.3M |
| Operating Margin | — | -1,315.5% | -239,692.2% | -1,101.9% | -313.9% | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-13.5M | $-4.1M | $-30.2M | $-30.9M | $-38.7M | $-27.4M | $-14.3M |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-13.4M | $-4.1M | $-30.2M | $-30.9M | $-38.7M | $-27.4M | $-14.3M |
| Net Margin | — | -1,300.7% | -41,430.9% | -1,074.2% | -309.5% | — | — | — |
| EPS (Basic) | — | $-1.20 | $-0.48 | $-4.15 | $-0.37 | $-0.63 | $-0.46 | $-0.49 |
| EPS (Diluted) | — | $-1.20 | $-0.48 | $-4.15 | $-0.37 | $-0.63 | $-0.46 | $-0.49 |
| Shares Outstanding (Basic) | 14.6M | 11.2M | 8.5M | 7.3M | 84.6M | 61.2M | 60.2M | 39.4M |
| Shares Outstanding (Diluted) | 14.6M | 11.2M | 8.5M | 7.3M | 84.6M | 61.2M | 60.2M | 39.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |